Veraxa Biotech (NASDAQ:VRXA) Director Oliver Rolf Baumann Acquires 50,000 Shares

Veraxa Biotech Holding AG (NASDAQ:VRXA) Director Oliver Rolf Baumann bought 50,000 shares of Veraxa Biotech stock in a transaction dated Thursday, August 27th. The shares were acquired at an average price of $1.50 per share, with a total value of $75,000.00. Following the completion of the purchase, the director directly owned 5,773,618 shares in the company, valued at $8,660,427. This trade represents a 0.87% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Veraxa Biotech Price Performance

VRXA stock opened at $1.35 on Tuesday. Veraxa Biotech Holding AG has a 1-year low of $1.32 and a 1-year high of $27.36.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Veraxa Biotech from a “sell” rating to a “hold” rating in a report on Monday.

About Veraxa Biotech

Veraxa Biotech AG is a biotechnology company focused on developing targeted antibody-based medicines, with an emphasis on antibody-drug conjugates (ADCs). These therapies are designed to use antibodies to identify specific cells and deliver therapeutic agents more selectively.

The company’s work includes antibody discovery, therapeutic development and the design of ADC candidates that combine targeting antibodies with drug payloads. Its research is directed primarily toward potential treatments for cancer and other serious diseases, although specific development programs and product approvals may change as its pipeline advances.

Publicly available information about Veraxa Biotech’s corporate history, geographic operations and leadership is limited.